Amoxicillin

證據等級: L5

預測適應症: 8 個

Amoxicillin: From Bacterial Infections to Monoclonal Gammopathy

One-Sentence Summary

Amoxicillin is a broad-spectrum aminopenicillin antibiotic widely used for treating bacterial infections of the respiratory, urinary, and gastrointestinal tracts, including Helicobacter pylori eradication regimens. The TxGNN model predicts it may be effective for Monoclonal Gammopathy — most specifically Immunoproliferative Small Intestinal Disease (IPSID), where antibiotic eradication of the bacterial antigenic driver produces disease remission. This direction is supported by 1 clinical trial and 11 publications, with the most compelling biological rationale concentrated in IPSID case series.

Quick Overview

Item	Content
Original Indication	Bacterial infections (respiratory, urinary, gastrointestinal tract; H. pylori eradication)
Predicted New Indication	Monoclonal Gammopathy — specifically IPSID (Alpha-chain disease / Mediterranean lymphoma)
TxGNN Prediction Score	99.22%
Evidence Level	L3
Malaysia Market Status	✓ Marketed
Number of Registrations	100
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data was not retrieved in this Evidence Pack. Based on established pharmacological knowledge, amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding irreversibly to penicillin-binding proteins (PBPs), preventing peptidoglycan cross-linking and causing bactericidal activity against a broad range of gram-positive and gram-negative organisms. This mechanism is the essential foundation for its potential role in antigen-driven lymphoproliferative disease.

The biological bridge to monoclonal gammopathy centres on a specific subtype: Immunoproliferative Small Intestinal Disease (IPSID), also known as Alpha-chain disease or Mediterranean lymphoma. In IPSID, persistent intestinal bacterial infection — particularly Campylobacter jejuni and related gram-negative organisms — drives abnormal clonal proliferation of IgA α-heavy-chain-secreting B cells, generating a detectable monoclonal immunoglobulin. When this bacterial antigenic driver is eradicated with antibiotics (tetracycline, amoxicillin ± metronidazole), early-stage disease (Stage A) can achieve durable complete remission without chemotherapy.

This mechanism closely parallels the well-validated H. pylori eradication model for gastric MALT lymphoma, and multiple published case series have documented full or partial regression of IPSID following antibiotic therapy alone (PMID 9030995, 8988128, 20300878), making this one of the few repurposing opportunities in this class that is already partially clinically validated. Critical caveat: this biological rationale applies exclusively to early-stage IPSID and does not extend to MGUS, multiple myeloma, Waldenström’s macroglobulinemia, or other monoclonal gammopathies, where amoxicillin has no established mechanistic role.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00062231	N/A	Terminated	351	Prospective double-blind RCT comparing moxifloxacin monotherapy vs. ciprofloxacin + amoxicillin/clavulanate as oral empirical therapy for febrile neutropenia in low-risk cancer patients; terminated early without a definitive conclusion. Amoxicillin used as part of the comparator combination — not as a treatment for monoclonal gammopathy directly.

Note: No clinical trials specifically investigating amoxicillin for IPSID or monoclonal gammopathy are currently registered. The trial above (Relevance Grade C) provides only contextual background on amoxicillin use in a haematology-oncology setting.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9030995	1997	Case Series	Lancet	Mediterranean lymphoma (IPSID) treated with antibiotics alone; documents complete regression of monoclonal B-cell disease after eradication therapy, establishing the antibiotic-treatment paradigm for early-stage IPSID
8988128	1997	Case Series	Lancet	Regression of immunoproliferative small intestinal disease following H. pylori eradication; directly supports the infection-driven clonal B-cell proliferation model
20300878	2010	Case Series	J Gastrointest Cancer	20-year-old male with alpha-heavy-chain IPSID achieved complete clinical and endoscopic regression following H. pylori eradication antibiotic therapy, with resolution of mesenteric lymphadenopathy on CT
16253033	2005	Case Report	Arch Pathol Lab Med	Non-secretory IPSID variant (extranodal marginal zone B-cell lymphoma) of the distal small bowel; highlights diagnostic spectrum and histopathological subtypes relevant to defining antibiotic-responsive candidates
21908119	2011	Case Report	Med Mal Infect	Rothia dentocariosa pneumonia in an immunocompromised patient with plasma cell dyscrasia; amoxicillin used for infectious complication management in a monoclonal gammopathy context
35619805	2022	Case Report	Front Public Health	Disseminated nocardiosis caused by Nocardia vulneris in a patient with macroglobulinemia; amoxicillin/clavulanate identified as one of the susceptible antibiotic options
22092390	2012	Retrospective Comparative Study	J Oral Pathol Med	Comparative analysis of bisphosphonate-related ONJ in multiple myeloma vs. breast cancer; amoxicillin used as supportive antibiotic in standardised wound care protocol
20015614	2010	Case Series	Int J Oral Maxillofac Surg	Surgical management of bisphosphonate-induced ONJ in myeloma patients unresponsive to conservative therapy; amoxicillin used as prophylactic/supportive antibiotic
20513124	2010	Diagnostic Accuracy Study	Am J Hematol	High false-positive rate of Aspergillus galactomannan test in multiple myeloma patients; amoxicillin/clavulanate implicated as a cause of assay interference — clinically relevant for infection monitoring in this population
18639371	2009	Retrospective Study	Br J Oral Maxillofac Surg	Bisphosphonate-associated ONJ in myeloma: therapy discontinuation does not alter clinical course and may allow recurrence of bone pain and osteolytic progression

Evidence Assessment: The three IPSID/Mediterranean lymphoma papers (PMID 9030995, 8988128, 20300878) provide the most directly relevant and mechanistically compelling evidence. The remaining publications reflect amoxicillin use in secondary infection management or supportive care within haematological malignancy contexts, and do not constitute primary repurposing evidence.

Malaysia Market Information

Amoxicillin is confirmed as marketed in Malaysia with 100 registered products. However, individual product registration details — including authorization numbers, product names, dosage forms, and approved indications — were not returned in this Evidence Pack.

Action Required: Retrieve full product listing from the Malaysia NPRA e-Search portal to confirm available formulations (oral, injectable, suspension), dosing strengths, and currently approved indications before proceeding.

Safety Considerations

Please refer to the package insert for safety information. Detailed warnings and contraindications data were not available in this Evidence Pack and should be retrieved directly from the NPRA-approved product labelling.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Amoxicillin has a biologically plausible, partially validated mechanism for treating early-stage IPSID (Stage A) through eradication of the bacterial antigenic driver sustaining clonal B-cell proliferation — a paradigm directly analogous to H. pylori eradication for gastric MALT lymphoma, supported by published case series demonstrating durable disease regression. The scope is deliberately narrow: this recommendation applies to IPSID only and must not be extrapolated to other monoclonal gammopathies.

To proceed, the following is needed:

Retrieve MOA data from DrugBank API (DB01060) to formally document the mechanistic basis and confirm absence of direct anti-lymphoproliferative activity
Retrieve NPRA product label PDF to extract full warnings, contraindications, and currently approved indications for Malaysia-specific labelling
Define strict patient selection criteria: early-stage IPSID (Stage A only) — explicitly excluding MGUS, multiple myeloma, and Waldenström’s macroglobulinemia from any expanded use proposal
Commission a focused systematic review of IPSID antibiotic therapy outcomes (amoxicillin vs. tetracycline vs. amoxicillin + metronidazole) to characterise the optimal regimen, dosing duration, and remission rates
Investigate regional epidemiology: IPSID / Mediterranean lymphoma has higher reported prevalence in Middle Eastern and some Southeast Asian populations, which may increase clinical relevance in the Malaysian context
Clarify TxGNN false-positive rate for the higher-ranked predictions (Ranks 1–5, all L5/Hold), as these appear to reflect knowledge-graph noise rather than genuine repurposing candidates, and refine the prediction pipeline accordingly
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.